Global Granisetron Market Size To Worth USD 13.05 Billion By 2033 | CAGR of 6.52%
Category: HealthcareGlobal Granisetron Market Size To Worth USD 13.05 Billion By 2033
According to a research report published by Spherical Insights & Consulting, the Global Granisetron Market Size is expected to grow from USD 6.94 billion in 2023 to USD 13.05 billion by 2033, at a CAGR of 6.52% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 270 pages with 115 Market data tables and figures & charts from the report on the "Global Granisetron Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Transdermal, Injection, and Oral), By Applications (Postoperative Nausea, Chemotherapy-Induced Nausea, and Radiation Induced Nausea), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies) and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/granisetron-market
The granisetron market is a growing area of research and development focused on the development, production, and distribution of granisetron medications used to prevent and treat nausea and vomiting from chemotherapy, radiation therapy, and post-operative conditions. These medications, classified as 5-hydroxytryptamine (5-HT3) receptor antagonists, are marketed under the names GraniCare, GRANITERO, and Granistorm. The increasing number of post-cancer cases is driving the demand for granisetron medications. The National Cancer Institute reports that chemotherapy-induced nausea and vomiting (CINV) is a common adverse event for cancer patients, causing significant morbidity and negatively impacting their quality of life. However, recent advancements in antiemetic medications have significantly reduced the incidence and severity of this complication, making it less feared. The growing global incidence of cancer is driving the growth of the granisetron market, as more people are aware that antiemetic treatments can enhance the quality of life for cancer patients. The pharmaceutical industry is investing in the development of sophisticated formulations and drug delivery systems for granisetron, giving producers a competitive edge and expanding the range of applications. However, the availability of antiemetic medication may impede market growth.
The oral segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the product type, the global granisetron market is categorized as transdermal, injection, and oral. Among these, the oral segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period. The growth of the segment is attributed to factors such as patient compliance, accurate dosing, controlled drug delivery, ease of administration, non-invasiveness, stability, handling, geriatric and pediatric dosage form suitability, cost-effectiveness, and rapid action.
The chemotherapy-induced nausea segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the applications, the global granisetron market is categorized as postoperative nausea, chemotherapy-induced nausea, and radiation-induced nausea. Among these, the chemotherapy-induced nausea segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The growth of the segment is attributed to the rising cancer prevalence, increased use of cancer treatments, increased emetogenic drug intake, and growing chemotherapy in healthcare sectors.
The hospital pharmacies segment accounted for the greatest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the applications, the global granisetron market is categorized as retail pharmacies, online pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment accounted for the greatest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment expansion is attributed to increased dispensing rates of granisetron, rising cancer prevalence, and acidity complications, leading to a rise in anti-emetic medication purchases.
North America is expected to hold the greatest share of the global granisetron market over the forecast period.
Get more details on this report -
North America is expected to hold the greatest share of the global granisetron market over the forecast period. North America dominates the granisetron market due to its high cancer prevalence and established healthcare system. The market is expanding rapidly due to large pharmaceutical companies, research and development focus, patient knowledge of antiemetic treatments, and favorable reimbursement policies.
Asia Pacific is predicted to grow at the fastest-growing region of the global granisetron market throughout the estimated period. The increasing prevalence of cancer and chronic illnesses, coupled with advancements in healthcare infrastructure, is driving market expansion. The demand for granisetron is expected to rise due to urbanization, rising healthcare costs in emerging economies like China and India, and rising awareness about supportive medicines and cancer care in the Asia Pacific region.
Major key players in the global granisetron market are Sun Pharmaceutical Industries, Ltd., Lupin Limited, Sandoz International GmbH, Hikma Pharmaceuticals PLC, Mylan N.V, Sanofi S.A, Torrent Pharmaceuticals, GlaxoSmithKline, Cipla Limited, Pfizer, Aurobindo Pharma Limited, Amneal Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In January 2022, Cumberland Pharmaceuticals received the FDA approval for oncology-supportive care medicine SANCUSO® (granisetron transdermal patch), the first and only prescription patch for preventing nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug, granisetron, dissolves in the adhesive and is released into the patient's bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (CINV). Alternative oral treatments must be taken multiple times to deliver the same therapeutic doses.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global granisetron market based on the below-mentioned segments:
Global Granisetron Market, By Product Type
- Transdermal
- Injection
- Oral
Global Granisetron Market, By Applications
- Postoperative Nausea
- Chemotherapy-Induced Nausea
- Radiation-Induced Induced Nausea
Global Granisetron Market, By Distribution Channel
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Global Granisetron Market, By Regional
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?